Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Australian watchdog takes GlaxoSmithKline, Novartis units to court

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/06/2017 | 12:26am CET
Swiss drugmaker Novartis' logo is seen in Stein

(Reuters) - The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline (>> GlaxoSmithKline) and Swiss healthcare company Novartis (>> Novartis) to court over false or misleading representations in the marketing of pain relief products.

(Reuters) - The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline (>> GlaxoSmithKline) and Swiss healthcare company Novartis (>> Novartis) to court over false or misleading representations in the marketing of pain relief products.

The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated".

"We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.

ACCC's concerns come as a price sampling conducted by it noted that supermarkets and pharmacies often sold Osteo Gel at a significant price premium to Emulgel.

The regulator is seeking declarations, injunctions, pecuniary penalties, and a publication order in relation to its allegations.

"The alleged conduct is particularly concerning, given the significant penalties handed down by the court against the makers of Nurofen for what we consider to be similar conduct,” Sims said.

In December last year, the Federal court of Australia upheld an appeal by the regulator against Reckitt Benckiser's (>> Reckitt Benckiser) Australian unit for similar charges on its Nurofen Specific Pain products, imposing a A$6 million (£3.40 million) penalty.

(Reporting by Susan Mathew in Bengaluru; Editing by Stephen Coates)

Stocks treated in this article : Novartis, Reckitt Benckiser, GlaxoSmithKline
Valeurs citées dans l'article
ChangeLast1st jan.
NOVARTIS -0.88% 79.28 Delayed Quote.-2.94%
RECKITT BENCKISER 0.75% 5913 Delayed Quote.-15.18%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
02/22GLAXOSMITHKLINE : GSK Inhaler Recall outside the US
AQ
02/22GLAXOSMITHKLINE : Ex-dividend day for for final dividend
FA
02/21GLAXOSMITHKLINE : recalls Ventolin Diskus inhalers
AQ
02/20GLAXOSMITHKLINE PLC : Today’s Research Reports on Trending Tickers: GlaxoSmithKl..
AC
02/16GLAXOSMITHKLINE : GSK submits landmark IMPACT data to European Medicines Agency ..
AQ
02/15GLAXOSMITHKLINE : Details Findings in Organic Research [High-Throughput Automate..
AQ
02/15GLAXOSMITHKLINE : An Application for the Trademark "ELEBRATO" Has Been Filed by ..
AQ
02/15FINDINGS FROM GLAXOSMITHKLINE PLC IN : Efficacy,...
AQ
02/15GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Provide New Insights into Bio..
AQ
02/15GLAXOSMITHKLINE : Investigators at GlaxoSmithKline plc Release New Data on Monoc..
AQ
More news
News from SeekingAlpha
02/21Tracking Tweedy Browne Portfolio - Q4 2017 Update 
02/21CytoDyn Makes Huge Stride For HIV Patients, Now Acts As A Potential Acquisiti.. 
02/21GlaxoSmithKline goes ex-dividend tomorrow 
02/20FDA tentatively OKs Mylan's HIV combo pill 
02/20AGENUS : Positioned To Rapidly Enhance Shareholder Value 
Financials ( GBP)
Sales 2018 30 206 M
EBIT 2018 8 317 M
Net income 2018 4 101 M
Debt 2018 13 333 M
Yield 2018 6,04%
P/E ratio 2018 15,34
P/E ratio 2019 13,94
EV / Sales 2018 2,62x
EV / Sales 2019 2,53x
Capitalization 65 676 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,2  GBP
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-1.47%91 577
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618